|
  
- 积分
- 97
- 威望
- 97
- 包包
- 3142
|

本帖最后由 bobo 于 2009-6-28 08:34 编辑 9 B4 H$ h; n# K% `
( }- i( Z' V. {. {0 E
表观遗传学与干细胞——2009年亚洲生物高峰论坛录制(音频mp3)5 u7 m6 i! I" o% G! @! D
9 Z O# u& i9 a6 l
4 e2 U9 D* n# u/ h. l( B; ~; e. z* _ u4 J& E/ u$ p( k
回复为ppt- v2 \. [# l$ v! O
摘要:- K! I. B* K* H2 R2 n
9 h0 V! M8 i6 K1 J; CHongkui Deng7 f& b6 M0 r! F! a1 P& _
; _0 T+ |' r' T& V+ q# X. SLaboratory of Stem Cell and Generative Biology, College of Life Sciences, Peking University, Beijing 100871, China.$ m3 a2 v0 `1 e W/ B
4 Z1 |, P+ p4 }* p( s
Human pluripotent stem cells represent a potentially unlimited source of functional pancreatic endocrine lineage cells. We established a new highly efficient approach to induce human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells to differentiate into mature insulin-producing cells in a chemical-defined culture system. The differentiated cells obtained by this approach comprised nearly 25% insulin-positive cells as assayed by flow cytometry analysis, which released insulin/C-peptide in response to glucose stimuli in a manner comparable to that of adult human islets. Most of these insulin-producing cells co-expressed mature beta cell-specific markers such as NKX6-1 and PDX1, indicating a similar gene expression pattern to adult islet beta cells in vivo. This work provides a new model to study the mechanism of human pancreatic specialization and maturation in vitro, and enhances the possibility of utilizing patient-specific iPS cells for the treatment of diabetes! a R0 {& m! T# l1 c# S" l. |
$ ~ v j: S! [# X
回复为ppt
) o. l' G& e1 o& a& i- y% u1 y, U3 `# y: P& w
' @) n& F5 j, K: x9 q2 Y6 t
3 m5 T) s7 X' Y3 G& A. c* F% n# z% T7 V: G' n
|
附件: 你需要登录才可以下载或查看附件。没有帐号?注册
|